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Abstract 
Acute myeloid leukemia (AML) is a heterogeneous 
clonal disorder with two prominent features: i) 
hematopoietic progenitor cells loose the ability to 
differentiate normally and ii) the transformed 
leukemia cells show an impaired regulation of 
myeloid proliferation.  
AML with myelodysplasia-related changes is a sub-
entity of AML that has a poor prognosis. It is 
characterized by a history of MDS, significant 
morphologic dysplasia, or MDS-related cytogenetic 
features such as -7/del(7q) and others.  Whereas the 
prognosis of AML is quite different with respect to 
genetic aberrations, the therapy - except of acute 
promyelocytic leukemia (APL) - is still relatively 
unchanged from 30 years ago. Therefore, new 
treatment strategies are needed. 
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Clinics and pathology 
Disease 
Acute myeloid leukemia with myelodysplasia 
related changes (AML-MRC) is a subgroup of AML. 
It was introduced in 2008 by the WHO classification 
and updated in 2016 (Weinberg et al., 2015). A 
diagnosis of AML-MRC requires ≥ 20% blasts and 
additionally one of the following three  
criteria:  
- history of myelodysplastic syndrome (MDS) or 
myelodysplastic/myeloproliferative neoplasm 
(MDS/MPN) 
- MDS-related cytogenetic abnormalities or 
 multilineage dysplasia (≥ 50% dysplastic cells in≥ 
two hematopoietic lineages) (Arber et al., 2016a). 
Etiology 
There are various risk factors which can cause AML 
in general. These risk factors can be categorized as 
genetic disorders, physical and chemical exposure, 
radiation therapy and chemotherapy. Even though 
many people are exposed, to various degrees, to 
carcinogens, only a few cases may present with a 
known history of carcinogen exposure. Currently, it 
is not fully understood why some people develop 
AML and some do not (Estey and Döhner, 2006). 
Genetically, many researchers favor the "two-hit" 
hypothesis first proposed by Hartmut Beug (Beug et 
al., 1978), and later by Gary Gilliland. This 
hypothesis states that for transformation, a mutation 
in a kinase coding gene such as RAS, KIT or FLT3 
has to occur together with a class II mutation 
targeting a transcription of nuclear factor such as 
NPM1, RUNX1 or CEBPA. Today, we know about 
a high variation of somatic mutations and 
chromosomal abnormalities characterizing different 
types of AML. AML-MRC is often associated with 
the following chromosomal abnormalities (Table 1) 
(Deschler et al., 2006; Weinberg et al., 2015). 
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Epidemiology 
If the WHO classification is strictly applied, 48% of 
all adult AML cases meet the AML-MRC criteria. It 
tends to affect more male and is a disease of the 
elderly with a median age of 68 years. Additionally, 
it is associated with a higher frequency of 
unfavorable cytogenetics and, consequently, a worse 
clinical outcome (Davis et al.,2013; Xu et al., 2014; 
Weinberg et al., 2009). AML-MRC occurs more 
often de novo then secondary to myelodysplasia 
(Vardiman and Reichard, 2015). 
Cytology 
AML-MRC cases commonly present with 
multilineage dysplasia. This is validated best with 
peripheral blood smears or bone marrow smears for 
identifying myeloid and erythroid dysplasia and 
bone marrow biopsy for identifying megakaryocytic 
dysplasia (Falini et al., 2016). Following the WHO 
classification an AML-MRC presents with ≥ 50 % 
dysplastic cells in at least two hematopoietic 
lineages. The dysplastic features are not unique for 
AML-MRC, but can be also detected in other 
hematopoietic diseases, such as MDS (Wu et al., 
2013). Dysplastic neutrophils may exhibit a nucleus-
cytoplasm dysynchrony, hypogranulation and 
abnormal nuclear segmentation (pseudo-Pelger-
Huët anomaly), e.g. bi-nucleated segments 
(Weinberg et al., 2015). As mentioned, 
dyserythropoesis and dysmegakaryopoesis are also 
commonly seen. Dyserythropoesis presents with odd 
erythroid precusors and sometimes ring sideroblasts, 
as well as multinuclearity, megaloblastoid changes 
and karyorrhexis. Dysmegakaryopoesis commonly 
shows hypolobulated micromegakaryocytes, non-
lobulated nuclei in megakaryocytes of all sizes and 
multiple widely separated nuclei (Wakui et al., 
2008). 
Treatment 
The therapy of AML-MRC is based on regular 
AML-therapy with a risk-adapted chemotherapy 
including induction chemotherapy ("7+3"; 
daunorubicine plus cytarabine) and postinduction 
therapy, such as high-dose cytarabine or in high-risk 
patients, allogeneic transplantation in first remission. 
Using regular assessments, lab studies including 
cytogenetics and molecular analyses, the patient can 
be assigned to a risk group and treatment and 
prognosis can be determined and the decision 
between curative chemotherapy/allogeneic stem cell 
transplantation, palliative chemotherapy and best 
supportive care can be made (Estey and Döhner, 
2006). Chemotherapy can be separated into two 
main parts. First, the induction therapy with the 
attempt to reach complete remission. Second, the 
consolidation therapy to prolong the complete 
remission. If the patient displays characteristics of 
high risk AML, a hematopoietic stem cell 
transplantation (HSCT) must be considered (Kumar, 
2011). As AML-MRC frequently fulfills the high-
risk criteria such as: 3(q21q26) abnormalities, 
RPN1/MECOM (EVI1), del(5q), del(7q), t(6;9), 
other 11q23 abnormalities, 17p abnormalities, or 
complex aberrant karyotypes described as at least 3 
unrelated abnormalities excluding cases with t(8;21), 
inv(16), and t(15;17), an allogeneic stem cell 
transplantation will be the post-induction therapy of 
first choice in most adults (Vardiman and Reichard, 
2015). 
Prognosis 
The myelodysplastic changes and MDS associated 
chromosomal abnormalities of AML-MRC are 
associated with a worse prognosis and lower rates of 
event-free survival and overall survival. However, it 
was shown that there is no difference in prognosis 
between patients with AML-MRC with a history of 
MDS and the remaining cases of AML-MRC 
(Weinberg et al., 2009; Arber et al., 2003). Besides, 
AML-MRC with the absence of cytogenetic 
abnormalities seem to have a better prognosis 
(Weinberg et al., 2009). Additionally, AML-MRC 
with NPM1 mutations and with or without 
cytogenetic abnormalities show a better prognosis 
(Haferlach et al., 2009). This was also shown for 
CEBPA mutations (Vardiman and Reichard, 2015). 
Therefore AML-MRC with NPM1 or CEBPA 
mutations are excluded from the AML-MRC 
category in the WHO classification 2016 (Arber et 
al., 2016). The prognosis of AML-MRC particularly 
in context of multilineage dysplasia remains 
controversial (Vardiman and Reichard, 2015).  In 
patients who have undergone allogenic HSCT there 
is no prognostic difference in AML-MRC patients 
compared to AML not otherwise specified (AML-
NOS) (Ikegawa et al., 2016). 
Cytogenetics 
Cytogenetics morphological 
Following the WHO classification, cases of AML 
with MDS-related cytogenetic abnormalities meet 
the criteria of AML-MRC. MDS and AML-MRC 
may show complex karyotype and with 
predominantly unbalanced chromosomal 
abnormalities (Vardiman and Reichard, 2015; 
Miesner et al., 2010). A complex karyotype is 
defined as three or more unrelated chromosomal 
abnormalities and is differentiated into unbalanced 
and balanced chromosomal abnormalities (see 
Figure 1). A complex karyotype can lead to aberrant 
expression pattern of regulating genes and is often 
associated with a poor prognosis. Likewise, it is 
assumed that autosomal monosomy (2 or more 
autosomal monosomies or 1 autosomal monosomy 
plus one or more other chromosomal abnormalities) 
is associated with a poor prognosis.  
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Figure 1.  Karyotype analysis with MDS related cytogenetic abnormalities: 
46,XX,t(4;6)(q21;23),del(5)(q11.2q35),del(7)(q11.2q36),+8,add(11)(p15),del(12)(p12p13),-17. Commonly seen in MDS is the 
deletion of 5 and 7 (stars) and/or monosomy 17 (cross) (Miesner et al., 2010). 
 
The most common monosomies in AML and MDS 
are monosomies 5 and 7 which are known for its 
poor prognosis (Takahashi, 2011; Cazzola et al., 
2013). Table 1 shows the commonly occurring 
balanced and unbalanced chromosomal 
abnormalities.  
Complex 
Karyotype 
>3 unrelated abnormalities, none 
of which are included in the 
AML with recurrent genetic 
abnormalities subgroup 
Unbalanced 
abnormalities 
-7/del(7q)  
-5/del(5q)  
i(17q)/t(17p)  
-13/del(13q)  
del(11q)  
del(12p)/t(12p)  
idic(X)(q13) 
Balanced 
abnormalities 
t(11;16)(q23;p13.3)  
t(3;21)(q26.2;q22.1)  
t(2;11)(p21;q23)  
t(1;3)(p36.3;q21.1)  
t(5;12)(q33;p12) 
t(5;7)(q33;q11.2)  
t(5;17)(q33;p13)  
t(5;10)(q33;q21)  
t(3;5)(q25;q34) 
Table 1. Cytogenetic abnormalities for AML with 
myelodysplasia-related features (modified from Vardiman 
and Reichard et al. 2015). 
Common gene arrangements and their effects are 
displayed in Table 2. According to the 2016 WHO 
classification the MDS related cytogenetic 
abnormality del(9q) is no longer considered a AML-
MRC defining abnormality. Since del(9q) 
commonly occurs together with NPM1 or bi-allelic 
CEBPA mutations it is also associated with a better 
outcome. The same is true for trisomy 8, del(20q) 
and loss of chromosome Y (Pabst et al., 2009; Wu et 
al., 2013). 
Gene 
arrangement 
Effect 
5q33  
activation of the platelet-
derived growth factor- β ( 
PDGFRB ) 
3q26 (MECOM 
(EVI1) locus) 
Impaired EVI1 expression 
(poor prognosis) 
3q21 (GATA2 
locus) 
Impaired EVI1 expression 
(poor prognosis) 
11q23 (KMT2A 
(MLL) locus) 
Clonal evolution and disease 
progression in acute leukemia 
t(3;5) fusion product NPM1 / MLF1 
Table 2.  Common gene arrangements in AML-MRC 
(Vardiman and Reichard, 2015; Arber et al., 2003; Heldin 
and Lennartsson, 2013; Zuo et al., 2016; Lim et al., 2010) 
Genes involved and 
proteins 
As mentioned in Prognosis, the NPM1 mutation can 
present with multilineage dysplasia and is associated 
with a better outcome. However, there are no genetic 
somatic mutations fully specific for AML-MRC. As 
the subcategory AML-MRC represents almost 50% 
of all AML cases there can be found all common 
somatic mutations of AML concomitantly. In case of 
an AML-MRC with a history of MDS commonly 
mutated genes in MDS should also be considered, 
e.g. SF3B1 which is associated with the formation of 
ring sideroblasts in MDS (Malcovati et al., 2014). 
Somatic mutations have prognostic value and are 
assumed to play a critical role in leukemogenesis. 
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They can affect signal transduction, DNA 
methylation, chromatin modification, transcriptional 
regulation, RNA splicing and cohesion- complexes. 
The most commonly mutated genes in AML are 
FLT3, NPM1, CEBPA besides many more (Cancer 
and Atlas, 2013; Malcovati et al., 2014). Following 
the 2016 WHO classification an AML-MRC with 
presence of NPM1 and bi-allelic CEBPA mutation is 
not considered a AML-MRC anymore as these gene 
mutations are associated with a better outcome 
(Arber et al., 2003; Haferlach et al., 2009; Pabst et 
al., 2009) In contrast FLT3 mutations are associated 
with genetic abnormalities and a worse clinical 
outcome (Bibault et al., 2015). 
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